Financial Results Announcement - CytoSorbents Corporation announced preliminary and unaudited financial results for the quarter and year ended December 31, 2024[4] - The press release detailing the financial results and business updates was issued on January 3, 2025[4] Regulatory and Filing Information - The financial results are not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934[4] - The press release is furnished as Exhibit 99.1 in the Form 8-K filing[4] Executive Signatory - The report was signed by Dr. Phillip P. Chan, Chief Executive Officer of CytoSorbents Corporation[7]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 MAUI LAND & PINEAPPLE COMPANY, INC. (Exact name of registrant as specified in its charter) Delaware 99-0107542 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 500 Office Road Lahaina, Maui, Hawaii 96761 (Address of principal executi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to ___________________ Commission File Number: 001-39126 CNS Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. (Exact name of registrant as specified in its charter) Delaware 46-5211056 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217 (Address of principal executive offices) (Zip Code) (210) 698-5334 OR ...

Financial Performance - Total product revenue for the year ended December 31, 2024, was $35.6 million, an increase of $4.5 million, or 15%, compared to $31.1 million in 2023[252]. - Gross profit for the year ended December 31, 2024, was approximately $25.1 million, an increase of $3.2 million, or 14%, compared to $22.0 million in 2023[256]. - Loss from operations improved by 47% to approximately $16.8 million for the year ended December 31, 2024, down from $31.9 million in 2023, due to revenue growth and a 22% reduction in total operating expenses[260]. - The company experienced a loss on foreign currency transactions of approximately $4.2 million for the year ended December 31, 2024, compared to a gain of approximately $1.9 million in 2023[262]. - The company recorded approximately $3.76 million in stock-based compensation expense for the year ended December 31, 2024, including 1,214,400 performance awards granted[280]. Expenses Management - Research and development expenses decreased by approximately $8.7 million, or 56%, to $6.9 million for the year ended December 31, 2024, primarily due to the completion of the STAR-T clinical trial[257]. - Selling, general and administrative expenses decreased by approximately $3.3 million, or 9%, to $35.0 million for the year ended December 31, 2024, mainly due to reductions in salaries and professional expenses[259]. - The company continues to manage resources proactively, focusing on regulatory submissions and maintaining tight control over expenditures[268]. - The company has adjusted its accounting policy for grants, retroactively reclassifying grant income as a reduction of research and development expenses[279]. Financing Activities - The company secured a $20 million credit facility in June 2024, with an initial tranche of $15 million available at closing[266]. - The company raised a total of $7.3 million through the Rights Offering and Series A Right Warrants, increasing unrestricted cash to $15.6 million as of December 31, 2024, compared to $3.3 million previously reported[270]. - The Rights Offering closed on January 10, 2025, raising gross proceeds of $6.25 million from the sale of 6.25 million Units, each comprising one share of common stock and two Right Warrants[271]. - Approximately 1.4 million Series A Right Warrants were exercised at an exercise price of $1.13 per warrant, generating an additional $1.6 million in gross proceeds[271]. - The Avenue Capital Group has committed to loan the company up to $20 million, with $15 million available in the first tranche and a second tranche of up to $5 million contingent on FDA approval[273]. - The proceeds from the Avenue Capital Commitment will be used to pay off existing debt and for working capital, with interest rates set at a minimum of 5% above the Prime Rate or 13.5%[275]. - The company is actively pursuing various financing sources, including equity and debt financing, to meet its increasing capital needs[272]. Regulatory and Operational Updates - The company submitted a De Novo medical device application for DrugSorb-ATR to the FDA on September 27, 2024, which was accepted for substantive review in October 2024[250]. - The company expects to receive regulatory approval for DrugSorb-ATR in the U.S. and Canada in 2025, which is critical for future capital requirements[272]. - As of December 31, 2024, the company had current assets of approximately $21.6 million and current liabilities of approximately $9.9 million[264]. - The company operates leased facilities in Princeton, New Jersey, and Berlin, Germany, with a monthly base rent of approximately $121,000 as of December 31, 2024[283].

EX-99.1 2 ped_ex991.htm PRESS RELEASE EXHIBIT 99.1 PEDEVCO Announces 2024 Financial Results HOUSTON, TX / ACCESSWIRE / March 31, 2025 / PEDEVCO Corp. (NYSE American: PED) ("PEDEVCO" or the "Company"), an energy company engaged in the acquisition and development of strategic, high growth energy projects in the U.S., today announced its financial results for the year ended December 31, 2024. Key Highlights Include: J. Douglas Schick, President and Chief Executive Officer of the Company, stated, "We are please ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-41778 LQR House Inc. (Exact name of registrant as specified in its charter) Nevada 86-1604197 (State or other jurisdicti ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 333-249833 Crown Electrokinetics Corp. (Exact name of registrant as specified in its charter) | Delaware | 47-5423944 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ____________ Commission file number: 001-35922 PEDEVCO Corp. (Exact Name of Registrant as Specified in Its Charter) Texas 22-3755993 (I.R.S. Emplo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-K _____________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ (Address of principal executive offices) (Zip Code) (206) 455-9504 (Regist ...